DIRS.INFO The most relevant business & tech news

☆ Bernie Sanders to grill Novo Nordisk CEO on why weight-loss drugs Ozempic and Wegovy can cost up to 15 times more in US
▼ + stars: | 2024-06-16 | by ( Nathan Rennolds | ) www.businessinsider.com time to read: +1 min

Bernie Sanders said the CEO of Novo Nordisk will testify on the cost of Ozempic and Wegovy. Lars Jørgensen will appear before the Senate Committee on Health, Education, Labor, and Pensions. Sanders, who chairs the committee, said the hearing would focus on the "outrageously high cost" of the drugs. AdvertisementUS Senator Bernie Sanders has announced that the CEO of Danish drug company Novo Nordisk will testify on the high cost of the weight-loss drugs Ozempic and Wegovy. The hearing will focus on what was described in the press release as the "outrageously high cost" of the drugs, which have soared in popularity over the last year.

Persons: Bernie Sanders, Wegovy, Lars Jørgensen, Sanders, —, Ozempic Organizations: Novo Nordisk, Health, Education, Labor, Service, Business Locations: Danish

☆ Top doctor warns against taking weight loss drugs such as Ozempic to get 'beach body ready' for summer
▼ + stars: | 2024-06-15 | by ( Nathan Rennolds | ) www.businessinsider.com time to read: +3 min

download the appSign up to get the inside scoop on today’s biggest stories in markets, tech, and business — delivered daily. Read previewOne of the UK's top doctors has warned people against taking weight loss drugs such as Ozempic to get "beach body ready" for summer, saying they should not be seen as a "quick fix." "Drugs including Ozempic and Wegovy should only be used by people prescribed them for obesity or diabetes. Nevertheless, weight loss drugs such as Ozempic and Wegovy have soared in popularity over the last year. AdvertisementThere are currently three semaglutide products approved by the US Food and Drug Administration — Ozempic injection, Wegovy injection, and Rybelsus tablets.

Persons: —, Stephen Powis, Powis, I'm, Vicky Price Organizations: Service, National Health Service, Business, NHS Confederation, Society for Acute, Novo Nordisk, Europe's, Statistics, US Food and Drug Administration Locations: England, London, Danish, Statistics Denmark

☆ Investors wonder if tech can keep lifting S&P 500 to new records this summer as some cracks emerge
▼ + stars: | 2024-06-14 | by ( Sarah Min | ) www.cnbc.com time to read: +6 min

Wall Street is wondering whether the tech rally that's pushed the S & P 500 through record after record this year can continue, even as some cracks emerge in the market outlook. .SPX YTD mountain S & P 500 near record highs A peek inside the major indexes also reveals a similar pattern. Information technology is the best-performing sector in the S & P 500 this week, gaining 6.2%. As it is, the S & P 500 is already above 5,400, having advanced more than 13% this year. Winners and losers market David Miller, investment chief at Catalyst Funds, also said the S & P 500 could end 2024 with a 17% or 18% gain.

Persons: Jeff Klingelhofer, it's, Klingelhofer, Brian Nick, Nick, Dave Sekera, Dave Donabedian, Donabedian, David Miller, Miller Organizations: Nasdaq, Nvidia, Dow Jones, Apple, Thornburg Investment Management, CNBC, Macro, Federal Reserve, Morningstar, CIBC Private Wealth, Catalyst Funds, Microsoft, Google, Visa, MasterCard, American Airlines, Delta Air Lines, Novo Nordisk, TransDigm, Index, Retail, Manufacturing, Housing, Philadelphia Fed, Kroger, Darden, PMI Locations: U.S, NAHB

☆ This portfolio chip stock is the second-best AI play behind Nvidia
▼ + stars: | 2024-06-13 | by ( Morgan Chittum | ) www.cnbc.com time to read: +2 min

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. "Behind Nvidia, it's the second-best way to play AI in the chips space," said Jeff Marks, the Club's director of portfolio analysis. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER .

Persons: Jim Cramer, Jerome Powell, Jeff Marks, Eli Lilly, Lilly, Jim Cramer's, Jim Organizations: CNBC, Broadcom, Management, Michigan, Club, Novo Nordisk, Bloomberg

☆ A successful Alzheimer's drug will help Eli Lilly join the $1 trillion club
▼ + stars: | 2024-06-11 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +7 min

Eli Lilly became the most valuable health-care company in the world on the back of its blockbuster diabetes and obesity drugs. The billions of dollars in Eli Lilly is investing in manufacturing capacity support the idea that the long-term opportunity is immense. Adding Eli Lilly to the market could help address some of the obstacles that limited Leqembi's sales early on. Eli Lilly, which has spent billions in search of a successful Alzheimer's treatment , had hoped for donanemab to be approved by now. A sign with the company logo sits outside of the headquarters campus of Eli Lilly and Company on March 17, 2024 in Indianapolis, Indiana.

Persons: Eli Lilly, donanemab, Eli Lilly's, Donanemab, Leqembi —, Biogen, —, Jim Cramer's, Ken Langone, Morgan Stanley, Cantor Fitzgerald, Leqembi, Jim Cramer, Jim, Scott Olson Organizations: Food and Drug Administration, FactSet, Novo Nordisk, FDA, GE Healthcare, CNBC, Company, Getty Locations: GLP, Indianapolis , Indiana

☆ Move over 'Magnificent 7,' the 'Fantastic 5' may offer higher earnings and return potential
▼ + stars: | 2024-06-06 | by ( Pia Singh | ) www.cnbc.com time to read: +6 min

Looking for a less risky way to find growth stocks amid all the artificial intelligence hype? Looking ahead, Thornburg expects the Fantastic Five's outperformance to continue, with the forward price-to-earnings ratio of the European group falling below the seven U.S. stocks starting in 2026 and running through 2028. The money manager also projected that the European group will increase earnings 18% a year over the next three years versus 14% for the "Mag 7." ASML, the biggest producer of the equipment used to manufacture semiconductors, makes "leading-edge" lithography equipment needed to produce AI chips, Anderson said. He manages the Thornburg International Growth Fund , a concentrated portfolio of high-quality companies based outside the U.S., which has gained 8.8% year-to-date.

Persons: Nicholas Anderson, Anderson, Thornburg, It's, it's, FactSet, ASML Organizations: Thornburg Investment Management, Novo Nordisk, ASML, LVMH, AstraZeneca, SAP, Nvidia, Big Tech, Microsoft, Apple, GLP, Nordisk, Taiwan Semiconductor, Bloomberg, Growth Fund Locations: U.S, Novo, Europe, Belgium

☆ Eli Lilly's Wegovy rival Zepbound will help make weight-loss drug market worth $130 billion by 2030, Goldman Sachs says
▼ + stars: | 2024-06-02 | by ( George Glover | ) www.businessinsider.com time to read: +1 min

The anti-obesity drug market will be worth $130 billion by 2030, Goldman Sachs said. New products such as Eli Lilly's Zepbound prompted the bank to raise its forecast. download the app Email address Sign up By clicking “Sign Up”, you accept our Terms of Service and Privacy Policy . AdvertisementThe market for weight-loss drugs such as Ozempic and Wegovy will keep surging due to new products including Eli Lilly's Zepbound, according to Goldman Sachs. In a research note the bank forecast that the sector will be worth $130 billion by 2030 — $30 billion higher than its previous projection.

Persons: Goldman Sachs, Eli Lilly's Zepbound, —, Wegovy, Eli Lilly, Chris Shibutani Organizations: FDA, pharma, Service, Nordisk, Business Locations: Danish

☆ The Kremlin is accused of waging a 'shadow war' against the West with incidents of Russian sabotage on the rise
▼ + stars: | 2024-05-31 | by ( Daniel Kochis | ) www.businessinsider.com time to read: +7 min

If true, the loss of a Polish shopping center by means of Russian arson would be shocking on its own. As NATO advances toward the July summit, it's become clear that more comprehensive discussions on addressing the Russian sabotage campaign must take place. Some of the earliest identified acts of Russian sabotage occurred in 2014 at ammunition depots in the Czech Republic killing two and causing $42.5 million in damage. Bulgaria has played a crucial role in supplying ammunition and shells to Ukrainian forces, especially in the early stages of the war. Matthias Merz/picture alliance via Getty ImagesWeapons and training facilities aiding Ukrainian forces are frequent targets.

Persons: —, Donald Tusk, MAXIM SHEMETOV, Kaja Kallas, it's, Hannah Beier, Ozempic, Abrams, Matthias Merz, Russia, John MacDougall, Daniel Kochis Organizations: Service, Business, Reuters Estonia's, West, NATO, Scranton Army, BAE Systems, Denmark's Novo Nordisk, BAE, US Army, Getty Images, Energy, NATO Pipeline System, Deutsche Bahn, Investigators, DB, Getty, Kremlin, Ukraine, Center, Hudson Institute, United Locations: Polish, Poland, Wroclaw, Lithuania, Russia, Moscow, Russian, Estonia, Czech Republic, Vrbětice, Bulgaria, Scranton, Pennsylvania, United Kingdom, Ukrainian, Ukraine, Norwegian, Baltic, Bellheim, Germany, Czech, Europe, Berlin, France, Washington, Eurasia, United States, NATO

☆ Goldman Sachs raises target on Eli Lilly: Here's why
▼ + stars: | 2024-05-30 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailGoldman Sachs raises target on Eli Lilly: Here's whyChris Shibutani, Goldman Sachs anlayst, joins 'Squawk on the Street' to discuss what gives the analyst the confidence Eli Lilly and Novo Nordisk can continue to perform, what happens to the anti-obesity industry in 2030, and how the market will evolve.

Persons: Goldman Sachs, Eli Lilly, Here's, Chris Shibutani, Goldman Sachs anlayst Organizations: Novo Nordisk

☆ Here are Thursday's biggest analyst calls: Apple, Nvidia, Salesforce, Amazon, Okta, Eli Lilly, Cava, PayPal & more
▼ + stars: | 2024-05-30 | by ( Michael Bloom | ) www.cnbc.com time to read: +7 min

Goldman Sachs initiates Abbott Labs as buy Goldman said Abbott is well positioned for growth. UBS reiterates Apple as neutral UBS said its checks show iPhone pressure remains in China and the U.S. for Apple. Goldman Sachs reiterates Eli Lilly as neutral Goldman raised its price target on Eli Lilly to $785 per share from $740. Goldman Sachs reiterates Salesforce as buy Goldman said it's sticking with the stock following earnings on Wednesday. Goldman Sachs initiates AstraZeneca, Novartis and Novo Nordisk as buy Goldman initiated several biotech company's on Thursday and says it sees "innovation momentum a key focus."

Persons: Baird, OKTA, Goldman Sachs, Abbott, Goldman, Piper Sandler downgrades Cava, Piper, Eli Lilly, Wells Fargo, Wells, Mizuho, Wedbush, Daiwa, Stifel, it's, Salesforce, CRM's, Redburn, Guggenheim, Generac Organizations: UBS, Apple, Mizuho, PayPal, Bank of America, Gross, Amicus, USM, First, Deutsche Bank, Deutsche, JPMorgan, Nvidia, Technology, Northland, AstraZeneca, Novartis, Novo Nordisk, of America, TAM, Guggenheim Locations: China, Corning, Northland, 4Q24

☆ The South Park jinx could be coming for high-flying weight-loss stocks
▼ + stars: | 2024-05-29 | by ( Matthew Fox | ) www.businessinsider.com time to read: +3 min

"One year after appearing on South Park, the median stock underperforms the S&P 500 by 7%," Spectra Markets said. South Park: The End of Obesity special released last week tackled the growing popularity of Ozempic and Mounjaro as Eric Cartman tries to get his hands on the hugely popular weight-loss drugs. Advertisement"One year after appearing on South Park, the median stock underperforms the S&P 500 by 7%," Spectra Markets President Brent Donnelly said. "South Park has a 20+ year history of capturing the cultural zeitgeist and it's impossible to argue that anything that is lampooned on South Park is not priced in," Donnelly said. But not all those featured on South Park saw their stock prices peak shortly thereafter, with Microsoft, Yelp, and Netflix bucking the trend.

Persons: —, Eric Cartman, Brent Donnelly, Donnelly, Eli Lilly, shouldn't Organizations: Service, Spectra Markets, Novo Nordisk, Twitter, Starbucks, Walmart, Microsoft, Netflix

Telehealth company Ro on Wednesday launched a new tracker to help patients find a popular class of weight loss and diabetes drugs called GLP-1s amid shortages of those treatments in the U.S. The supply tracker could be a valuable tool for many Americans scrambling to get their hands on GLP-1s, such as Novo Nordisk 's weight loss injection Wegovy and diabetes drug Ozempic. The tracker aims to make GLP-1 supply information more transparent and accessible for everyone, regardless of whether they are enrolled in any of Ro's programs. The tracker is an interactive tool that gives people real-time supply information by drug, dose size and pharmacy location. He added that opening up the tracker to everyone also makes it more likely for both Ro patients and people not enrolled in the company's programs to access GLP-1s.

Persons: Ro, Eli Lilly, Zachariah Reitano, Reitano Organizations: Wednesday, U.S, Novo Nordisk, U.S . Food, Drug Administration, CNBC Locations: U.S

☆ Lightning Round: Apple is a buy here, says Jim Cramer
▼ + stars: | 2024-05-28 | by ( Jim Cramer | ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailLightning Round: Apple is a buy here, says Jim Cramer'Mad Money' host Jim Cramer weighs in on stock including: Datadog, Axcelis Technology, Tegna, Apple, Novo Nordisk, Bristol-Myers Squibb and more.

Persons: Jim Cramer Organizations: Axcelis Technology, Apple, Novo Nordisk, Myers Squibb Locations: Bristol

☆ Cramer's Lightning Round: Apple is a buy
▼ + stars: | 2024-05-28 | by ( Julie Coleman | ) www.cnbc.com time to read: +1 min

Stock Chart Icon Stock chart icon Datadog's year-to-date stock performance. Stock Chart Icon Stock chart icon Axcelis Technologies' year-to-date stock performance. Stock Chart Icon Stock chart icon Tegna's year-to-date stock performance. Stock Chart Icon Stock chart icon Bristol-Myers' year-to-date stock performance. Stock Chart Icon Stock chart icon Palantir's year-to-date stock performance.

Persons: Let's, Myers, Rowe Price's, Rowe Price Organizations: Technologies, Axcelis Technologies, Novo, Novo Nordisk, Bristol, Myers, Pfizer Locations: Bristol

☆ This new weight loss drug ETF bets big on two of the industry's leading players
▼ + stars: | 2024-05-27 | by ( Anna Gleason | ) www.cnbc.com time to read: +1 min

A top exchange-traded fund provider is betting on the long-term popularity of GLP-1 weight loss drugs. Roundhill Investments' GLP-1 & Weight Loss ETF (OZEM), which began trading last week, pairs leaders Eli Lilly and Novo Nordisk with players developing new treatments for weight loss and diabetes. Eli Lilly and Novo Nordisk each hold a roughly 20% weighting in the ETF, per Roundhill's website as of Friday. Mazza waived concerns that investors have missed out on the rally, noting the weight loss drug industry is still in its "early days." After last Tuesday's launch, shares of Roundhill's GLP-1 & Weight Loss ETF ended the week down by almost 2%.

Persons: Eli Lilly, Dave Mazza, Mazza, CNBC's Organizations: Investments, Novo Nordisk, Zealand Pharma, Amgen, Chugai Pharmaceutical Locations: Roundhill's

☆ Ozempic doesn't make everyone thin. That opens up an opportunity for some stocks
▼ + stars: | 2024-05-27 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +7 min

Or, in other cases, it can open the door to new options for the treatment of obstructive sleep apnea. Treating obesity and addressing sleep apnea Sleep apnea is a serious sleep disorder that results in interrupted breathing, preventing patients — and even their sleeping partners — from getting restful and restorative sleep. Obstructive sleep apnea, the most common form, occurs when muscles in the throat relax and collapse preventing air flow. Before qualifying for the device, patients usually need to have tried treatment with a CPAP machine and an oral device and been unsuccessful. He downgraded Inspire shares to hold at the beginning of the year due to this uncertainty he was anticipating.

Persons: Eli Lilly's Zepbound, Anthony Petrone, Medical's, Eli Lilly, Tim Herbert, Zepbound, Herbert, FactSet, Petrone, UnitedHealth, Jonathan Block Organizations: Novo Nordisk's, Mizuho Securities, CNBC, Systems, Inspire, American Diabetes Association, Drug Administration, National Institutes of Health, BMI Locations: U.S

In addition to Wegovy and Ozempic, the GLP-1 class includes Eli Lilly's highly popular weight loss drug Zepbound and diabetes treatment Mounjaro. VanGilder signed up nearly four years ago and started taking the weekly diabetes injection Ozempic specifically for weight loss. The big difference between Calibrate and prior weight loss efforts, VanGilder said, is that she doesn't feel like she's dieting. Calibrate is one of the only companies to regularly release reports detailing the results of its weight loss program. The federal Medicare program by law can't cover weight loss drugs unless the prescription is for another approved health benefit, such as diabetes or cardiovascular health.

Persons: Michael Siluk, Gray Beard, She'd, that's, Beard, wouldn't, She's, Ro, Goldman Sachs, Eli Lilly's, it's, Andrew Dudum, There's, Zachariah Reitano, Reitano, Wegovy, WeightWatchers, Gary Foster, Foster, Oprah Winfrey's, Kim Gradwell, Lee Smith, Jennifer VanGilder, she'd, Jenny Craig, VanGilder, I've, Kristin Baier, Rob MacNaughton, Ro's Reitano, we'd, Eli Lilly, Craig Primack, Primack, Hims, Dudum, We're Organizations: — Novo, UCG, Novo Nordisk, CNBC, Teladoc Health, World Health Organization, Food, WeightWatchers Clinic, Ursinus College, Asset Management Locations: Charlotte , North Carolina, U.S, Dudley , North Tyneside, Britain, Collegeville , Pennsylvania, Hims

☆ Eli Lilly's big GLP-1 investment — plus, what we want from 4 portfolio stock earnings
▼ + stars: | 2024-05-24 | by ( Matthew J. Belvedere | ) www.cnbc.com time to read: +3 min

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. Wall Street was bouncing higher Friday after, as Jim Cramer put it, a "really bad day" in the prior session. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, Thursday's, Goldman Sachs, Cramer, Eli Lilly, Locker, Mary Dillon, Nike isn't, Jim Cramer's, Jim Organizations: CNBC, Nvidia, Novo Nordisk, Costco, Nike, Jim Cramer's Charitable Locations: America, Indiana

☆ Ozempic reduces risk of serious illness and death in people with diabetes and kidney disease, study finds
▼ + stars: | 2024-05-24 | by ( Deidre Mcphillips | ) edition.cnn.com time to read: +8 min

Diabetes is a key risk factor for kidney disease, which is one of the leading causes of death in the United States and worldwide; about 1 in 3 people with diabetes also has chronic kidney disease, according to the US Centers for Disease Control and Prevention. But new research shows that weekly injections of semaglutide cut the risk of severe outcomes from diabetic kidney disease by about 24%. The new study found even broader related benefits of semaglutide treatment among people with diabetic kidney disease. “Kidney disease attributed to diabetes, or diabetic kidney disease, is one of the most common and deadly complications of diabetes. Yet, unfortunately, there’s very low awareness around it,” said Dr. Katherine Tuttle, chair of the Diabetic Kidney Disease Collaborative for the American Society of Nephrology.

Persons: ”, Vlado Perkovic, “ Semaglutide, Martin Holst Lange, Katherine Tuttle, ” It’s, Tuttle, semaglutide, It’s, Dr, Sanjay Gupta, White, ” Tuttle Organizations: CNN, Diabetes, US Centers for Disease Control, New England, of Medicine, European Renal Association Congress, University of New, University of New South Wales Sydney, Novo Nordisk, American Society of Nephrology, Providence Inland Northwest Health, Health Sciences, University of Washington, CNN Health Locations: United States, University of New South, Danish, American

☆ Ozempic Cuts Risk of Chronic Kidney Disease Complications, Study Finds
▼ + stars: | 2024-05-24 | by ( Dani Blum | ) www.nytimes.com time to read: +1 min

Semaglutide, the compound in the blockbuster drugs Ozempic and Wegovy, dramatically reduced the risk of kidney complications, heart issues and death in people with Type 2 diabetes and chronic kidney disease in a major clinical trial, the results of which were published on Friday. The findings could transform how doctors treat some of the sickest patients with chronic kidney disease, which affects more than one in seven adults in the United States but has no cure. The trial, funded by Ozempic maker Novo Nordisk, was so successful that the company stopped it early. Dr. Martin Holst Lange, Novo Nordisk’s executive vice president of development, said that the company would ask the Food and Drug Administration to update Ozempic’s label to say it can also be used to reduce the progression of chronic kidney disease or complications in people with Type 2 diabetes. Diabetes is a leading cause of chronic kidney disease, which occurs when the kidneys don’t function as well as they should.

Persons: Ozempic, ”, Katherine Tuttle, Martin Holst Lange, Novo, Subramaniam Pennathur Organizations: University of Washington School of Medicine, Renal Association, The New England, of Medicine, Novo Nordisk, and Drug Administration, Diabetes, Michigan Medicine Locations: United States, Stockholm, The

☆ This overlooked obesity-drug stock has 80% upside, JPMorgan says
▼ + stars: | 2024-05-21 | by ( Matthew Fox | ) www.businessinsider.com time to read: +3 min

Structure Therapeutics is an overlooked stock that could surge on the GLP-1 weight loss craze. "Meaningful upside from even a small piece of unprecedentedly large GLP-1 market," JPMorgan said. AdvertisementStructure Therapeutics is developing the drug candidate dubbed "1290," which is a "pure-play option" for the GLP-1 weight loss market, according to JPMorgan. JPMorgan said early results suggest the drug candidate offers "on par" weight loss results for patients with "no major concerns on safety." Advertisement"We think GPCR's market share in the oral market can approach 5% over time in an unprecedentedly large market.

Persons: —, Eli Lilly, Eli, orforglipron, Eli Lilly's Organizations: Therapeutics, JPMorgan, Service, Novo Nordisk, GLPP, Nasdaq

☆ JPMorgan says there's a new GLP-1 drug player and its shares can rally 80%
▼ + stars: | 2024-05-21 | by ( Pia Singh | ) www.cnbc.com time to read: +2 min

Structure Therapeutics is an overlooked player in the GLP-1 market, and could one day boast a competitive product and go up against Eli Lilly and the like, according to JPMorgan. Analyst Hardik Parikh initiated research coverage on the clinical stage drug developer with an overweight rating and $65 price target, implying 82% potential upside. According to Parikh, Structure's current $1.7 billion market value undervalues 1290's peak sales opportunity to generate more than $1 billion by 2035. Parikh estimated that Structure will launch 1290 for Type 2 diabetes, or T2D, after 2029. Additionally, Parikh thinks Structure could be an attractive partnership opportunity for larger drug companies looking to get involved in the market for obesity and Type 2 diabetes treatments.

Persons: Eli Lilly, Hardik Parikh, Parikh, Eli Lilly's Organizations: Therapeutics, JPMorgan, pharma, Novo Nordisk, Parikh Locations: T2D

☆ People using popular drugs for weight loss, diabetes are more likely to be diagnosed with stomach paralysis, studies confirm
▼ + stars: | 2024-05-20 | by ( Brenda Goodman | ) edition.cnn.com time to read: +9 min

Injected medications called GLP-1 agonists are in high demand because they have proved to be so effective for weight loss. The difference, which was statistically significant, amounted to a 52% increased risk of being diagnosed with stomach paralysis while on a GLP-1 medication. Compared with those who were not taking a GLP-1 medication, those who did were about 66% more likely to be diagnosed with gastroparesis. This study found that 0.53% of patients on GLP-1 medications were diagnosed with stomach paralysis, or about 1 case of gastroparesis for every 200 people taking the drugs. People taking GLP-1 medications were also more likely to have nausea and vomiting or gastroesophageal reflux disease (GERD) and to be prescribed a proton pump inhibitor.

Persons: gastroparesis, GERD, ”, Prateek Sharma, Sharma, ” Sharma, Michael Camilleri, “, Camilleri, It’s, who’d, Dr, Sanjay Gupta, it’s Organizations: CNN, Drugmaker, Nordisk, University Hospitals, Diabetes, University of Kansas, University of Kansas School of Medicine, American Society, Mayo Clinic, CNN Health Locations: Washington, Cleveland, GLP, Mayo

Digital pharmacy startup Hims & Hers Health is introducing access to compounded GLP-1 weight loss injections, the company announced Monday. The company, which offers a range of direct-to-consumer treatments for conditions like erectile dysfunction and hair loss, launched a weight loss program in December. But GLP-1 medications — the class of drugs like Ozempic and Wegovy that have skyrocketed in popularity — were not previously offered as part of that program. Customers can access the compounded GLP-1 medications via a prescription from a licensed healthcare providers on the Hims & Hers platform. The company's oral medication kits start at $79 a month, and its compounded GLP-1 injections will start at $199 a month.

Persons: Andrew Dudum, Dudum Organizations: Novo Nordisk, FDA, U.S . Food, Drug Administration, CNBC, & $ Locations: U.S

☆ Roche says weight loss drug shows promising results in early trial
▼ + stars: | 2024-05-16 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Roche on Thursday said its experimental weight loss drug showed promising results in an early-stage trial, boosting the company's bid to compete in the booming market for those treatments. But its weekly weight loss injection, called CT-388, is still years away from entering the market. The treatment works by mimicking the effect of two gut hormones — GLP-1 and GIP — to suppress a person's appetite, just like Eli Lilly's popular weight loss drug Zepbound and diabetes injection Mounjaro. Scientists have hypothesized that targeting those two hormones could have a meaningful effect on weight loss and blood sugar levels with fewer side effects than drugs that only target GLP-1, such as Novo Nordisk's weight loss treatment Wegovy. Eli Lilly's Zepbound delivered up to 22% weight loss after 72 weeks, while Novo Nordisk's Wegovy has led to 15% weight loss after 68 weeks.

Persons: Roche, Eli Lilly, Roche's, —, Eli Lilly's, Eli Lilly's Zepbound, Novo Nordisk's Wegovy Organizations: Roche, AG, Carmot Therapeutics, Novo Nordisk, Novo Nordisk's Locations: Basel, Switzerland, Swiss, Roche's, Novo

Search resuls for: "nordisk"

25 mentions found